Phase 1 clinical trials of osimertinib demonstrated a response rate of 61% and a disease control rate of 95% in advanced lung cancer patients with prevailing cancer progression after EGFR TKI treatment [14]. The gene discussed is EGFR; the disease is lung carcinoma.